Six Years of Mesothelioma Immunotherapy: From First Approval to 2026

For 16 years between 2004 and 2020, mesothelioma treatment did not meaningfully change. The standard of care was cisplatin combined with pemetrexed, a regimen that extended median survival by about three months over older options and left most patients with few choices when it stopped working.

That era ended on October 2, 2020, when the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as first-line treatment for unresectable pleural mesothelioma. It was the first new first-line treatment for the disease in more than a decade, and it was the first immunotherapy regimen the FDA had ever approved for mesothelioma.

The six years since have brought more change to the mesothelioma treatment landscape than the previous thirty. Here is the full timeline.

The Timeline: 2020 to 2026

2020: The First Approval

The approval of nivolumab plus ipilimumab was based on the Phase 3 CheckMate-743 trial, which enrolled 605 patients with previously untreated, unresectable pleural mesothelioma. Half received the immunotherapy combination, the other half received standard platinum doublet chemotherapy.

Median overall survival was 18.1 months in the immunotherapy arm compared to 14.1 months with chemotherapy. The benefit was most pronounced in patients with non-epithelioid cell types, where immunotherapy more than doubled median survival (18.1 months versus 8.8 months).

Nivolumab blocks PD-1, a checkpoint receptor on T cells. Ipilimumab blocks CTLA-4, a different checkpoint. By releasing both brakes on the immune system, the combination allows T cells to recognize and attack mesothelioma cells more effectively. Chemotherapy was not given with the immunotherapy, marking a shift away from the decades-old pemetrexed backbone for patients who responded to the immune approach.

2021: Second-Line and Durvalumab

Two additional trials reshaped the landscape in 2021.

The CONFIRM trial tested single-agent nivolumab against placebo in patients whose mesothelioma had progressed after first-line treatment. Median overall survival was 10.2 months on nivolumab compared to 6.9 months on placebo, a meaningful improvement for a population with no standard second-line options.

The DREAM trial, published the same year, tested durvalumab (a PD-L1 inhibitor) combined with first-line chemotherapy. Median overall survival reached 21 months, higher than either chemotherapy alone or the nivolumab-ipilimumab combination in cross-trial comparisons. The approach set up a Phase 3 trial (DREAM3R) to confirm the benefit.

2023: Pembrolizumab Joins the Mix

The KEYNOTE-483 trial tested pembrolizumab plus chemotherapy against chemotherapy alone in first-line pleural mesothelioma. Median overall survival improved from 16.1 months to 17.3 months, a modest but statistically significant gain.

Pembrolizumab was not adopted as a standard first-line option the way nivolumab-ipilimumab had been, partly because the CheckMate-743 approach had already established itself and partly because the survival benefit was smaller. But the trial confirmed that multiple checkpoint approaches could improve outcomes.

2024 to 2025: Longer Follow-Up, New Compounds

Extended follow-up data from CheckMate-743 showed that the immunotherapy benefit held over time. At three years, 23% of patients in the immunotherapy arm were alive compared to 15% on chemotherapy.

In parallel, new compounds began entering Phase 2 trials. BNT327 (PM8002), a bispecific antibody that simultaneously blocks PD-L1 and VEGF-A, produced a 52% response rate in 31 previously untreated patients. The results were presented at the 2025 ASCO Annual Meeting.

ADI-PEG20, a drug that depletes arginine from mesothelioma cells that cannot synthesize it (about 50% of cases), showed improved progression-free survival in the Phase 3 ATOMIC-Meso trial. The compound represented a different approach entirely: metabolic vulnerability rather than immune activation.

2026: Five-Year Data and Mechanistic Insights

Five-year follow-up from CheckMate-743 showed that 14% of patients on nivolumab plus ipilimumab were alive at five years, compared to 6% on chemotherapy. For a cancer where the overall five-year survival rate is approximately 12%, a 14% rate in a clinical trial population represents meaningful long-term benefit.

Mature Phase 2 data for BNT327 confirmed and extended the earlier results. At 20 months median follow-up, the overall response rate held at 52%, and median progression-free survival reached 16.6 months, compared to 6.8 months for the nivolumab-ipilimumab combination in CheckMate-743. In peritoneal mesothelioma, a subtype with no specifically approved treatments, BNT327 produced a 75% response rate and 100% disease control.

In April 2026, a preclinical study in Scientific Reports (Nature) provided a biological explanation for why checkpoint therapy works differently in pleural and peritoneal mesothelioma. Researchers found that the peritoneal cavity creates an immune-suppressive microenvironment that resists single-agent checkpoint drugs.

The finding helps explain why dual-mechanism approaches like BNT327, which targets both the checkpoint and the tumor blood supply, appear especially effective in peritoneal disease.

What Has Not Changed

Despite six years of progress, key gaps remain.

No immunotherapy has been specifically approved for peritoneal mesothelioma. Most Phase 3 trials still exclude peritoneal patients, leaving them dependent on off-label use of drugs approved for pleural disease.

Response rates to first-line immunotherapy still hover between 40% and 55% in pleural disease. More than half of patients do not respond to the best available options, and durable responses (the kind that translate to long-term survival) remain the exception.

Biomarkers that reliably predict who will respond to checkpoint therapy have not emerged. PD-L1 expression, widely used as a biomarker in other cancers, shows only weak correlation with response in mesothelioma.

What Comes Next

Three areas of development look most promising heading into the second half of 2026:

Bispecific antibodies. BNT327 is not the only drug of its class in development. Several companies are pursuing dual-targeting approaches that combine checkpoint blockade with inhibition of tumor blood vessels, angiogenesis, or other mechanisms.

CAR-T and cell therapies. Multiple Phase 1 trials are testing engineered T cells against mesothelin, a protein expressed on nearly all mesothelioma cells. Early data have been mixed, but the approach remains under active investigation.

Microenvironment sensitization. The 2026 Nature findings suggest that combination approaches targeting macrophages, B cells, or other components of the tumor microenvironment may be needed to extend immunotherapy benefit to peritoneal disease and to non-responders overall.

Six years ago, people with mesothelioma had one first-line option and no approved second-line treatments. Today they have approved immunotherapy, multiple Phase 2 regimens showing promise, and a growing biological understanding of why the disease responds differently across subtypes. The treatment landscape is moving faster than it ever has.

What patients need next are larger trials, more biomarkers, and approval pathways that include peritoneal disease. For families in states with the highest case volumes, including Illinois (670 exposure sites, ranked sixth nationally) and Texas, understanding these treatment advances is especially urgent.